Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Shareholder Urges Replacement of Vivus Board

By Pharmaceutical Processing | June 25, 2013

NEW YORK (AP) — Shares of Vivus Inc. fell Monday after its largest stakeholder sent a letter to the obesity drug maker’s shareholders urging them to replace the company’s board with a slate of nominees.

First Manhattan Co., which owns an about 9.9 percent stake in Vivus, said in its letter that the company is “hemorrhaging cash.” The New York-based investment firm has nominated nine people to Vivus’ board in a bid to replace the company’s entire board.

The firm has criticized Vivus for the failed launch of weight loss drug Qsymia. The Food and Drug Administration approved Qsymia in July, and Vivus started selling the drug in September.

It was the second long-term weight loss drug approved in the U.S. since 1999, but sales have not lived up to expectations. In part that’s because insurance coverage remains limited and out-of-pocket costs for patients are high. Qsymia also can’t be dispensed at pharmacies and is only available through mail order.

In addition, attempts to get the drug approved for use in Europe have been so far unsuccessful.

Vivus issued a statement later on Monday saying that its board and management have made “substantial progress” with Qsymia and the company is well positioned to drive future sales of the drug. It said the next stage of the process will be critical to the company’s success, adding that it’s in talks with major drug companies to expand its reach with primary-care physicians.

“The company is confident that its management team is best equipped to execute through this critical phase of (Vivus’) commercialization,” it added.

Vivus shareholders will vote on board members at the Mountain View, Calif., company’s annual meeting on July 15.

Vivus’ stock ended down 82 cents, or 6 percent, at $13.02 after dropping as low as $12.79 earlier in the day. Over the past year, the company’s shares have lost about 51 percent of their value.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE